Nord/LB Analysts Give Bayer (FRA:BAYN) a €64.00 Price Target

Nord/LB set a €64.00 ($74.42) price target on Bayer (FRA:BAYN) in a research note published on Wednesday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

Other equities analysts have also recently issued research reports about the company. Warburg Research set a €61.00 ($70.93) price objective on Bayer and gave the company a neutral rating in a report on Wednesday. DZ Bank restated a neutral rating on shares of Bayer in a report on Wednesday, July 31st. HSBC set a €63.00 ($73.26) price objective on Bayer and gave the company a neutral rating in a report on Wednesday, August 7th. Sanford C. Bernstein set a €90.00 ($104.65) price objective on Bayer and gave the company a buy rating in a report on Friday, August 9th. Finally, Credit Suisse Group set a €70.00 ($81.40) price objective on Bayer and gave the company a buy rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of €81.43 ($94.69).

BAYN opened at €66.59 ($77.43) on Wednesday. The business has a fifty day moving average of €60.79 and a 200 day moving average of €61.00. Bayer has a 52-week low of €91.58 ($106.49) and a 52-week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Green Investing

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.